{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T04:02:17Z","timestamp":1776312137041,"version":"3.50.1"},"reference-count":43,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Millions of women still use postmenopausal hormone therapy (HT). We genotyped 2090 women in Heart and Estrogen\/progestin Replacement Study for functional polymorphisms in GP1BA and GP6 and assessed the coronary heart disease (CHD) event rate over 5.8 years of follow-up. In patients receiving placebo, there was an increased CHD death\/myocardial infarction (MI)\/unstable angina (UA) event rate in carriers of the GP1BA \u22125C allele (adjusted [adj] P = .006). HT increased the hazard ratio (HR) of CHD events in patients with the GP1BA \u22125TT genotype by 16% and reduced the HR in patients with the TC+CC genotypes by 46% (adj interaction P &lt; .001). HT reduced the HR in patients with the GP6 13254TT genotype by 17% but increased the HR in patients with the TC+CC genotypes by 35% (adj interaction P &lt; .001). Furthermore, HT increased the HR of CHD events in patients with the GP1BA \u22125TT plus GP6 13254TC+CC genotypes by 57% and reduced the HR in patients with the GP1BA \u22125TC+CC plus GP6 13254TT genotypes by 55% (adj interaction P &lt; .001). In postmenopausal women with established CHD, these polymorphisms of platelet genes were predictors of CHD events and significantly modified the effects of HT on CHD risk. It will be important to replicate these findings in other studies.<\/jats:p>","DOI":"10.1182\/blood-2006-03-013151","type":"journal-article","created":{"date-parts":[[2006,11,14]],"date-time":"2006-11-14T23:13:44Z","timestamp":1163546024000},"page":"1862-1869","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":42,"title":["Effect of genetic variations in platelet glycoproteins Ib\u03b1 and VI on the risk for coronary heart disease events in postmenopausal women taking hormone therapy"],"prefix":"10.1182","volume":"109","author":[{"given":"Paul F.","family":"Bray","sequence":"first","affiliation":[{"name":"Jefferson Medical College and the Cardeza Foundation for Hematologic Research, Philadelphia, PA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy D.","family":"Howard","sequence":"additional","affiliation":[{"name":"Wake Forest University School of Medicine, Winston-Salem, NC;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Vittinghoff","sequence":"additional","affiliation":[{"name":"University of California at San Francisco, Department of Epidemiology and Biostatistics, San Francisco, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David C.","family":"Sane","sequence":"additional","affiliation":[{"name":"Wake Forest University School of Medicine, Winston-Salem, NC;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Herrington","sequence":"additional","affiliation":[{"name":"Wake Forest University School of Medicine, Winston-Salem, NC;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2006,11,14]]},"reference":[{"key":"2019111713463060700_B1","doi-asserted-by":"crossref","unstructured":"Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med1992; 117:1016\u20131037.","DOI":"10.7326\/0003-4819-117-12-1016"},{"key":"2019111713463060700_B2","doi-asserted-by":"crossref","unstructured":"Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women: Heart and Estrogen\/progestin Replacement Study (HERS) Research Group. JAMA1998; 280:605\u2013613.","DOI":"10.1001\/jama.280.7.605"},{"key":"2019111713463060700_B3","doi-asserted-by":"crossref","unstructured":"Viscoli CM, Brass LM, Kernan WN, et al. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med2001; 345:1243\u20131249.","DOI":"10.1056\/NEJMoa010534"},{"key":"2019111713463060700_B4","doi-asserted-by":"crossref","unstructured":"Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med2000; 343:522\u2013529.","DOI":"10.1056\/NEJM200008243430801"},{"key":"2019111713463060700_B5","doi-asserted-by":"crossref","unstructured":"Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med2003; 349:523\u2013534.","DOI":"10.1056\/NEJMoa030808"},{"key":"2019111713463060700_B6","doi-asserted-by":"crossref","unstructured":"Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA2004; 291:47\u201353.","DOI":"10.1001\/jama.291.1.47"},{"key":"2019111713463060700_B7","doi-asserted-by":"crossref","unstructured":"Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med1992; 326:242\u2013250.","DOI":"10.1056\/NEJM199201233260406"},{"key":"2019111713463060700_B8","doi-asserted-by":"crossref","unstructured":"Ruggeri ZM. Platelets in atherothrombosis. Nat Med2002; 8:1227\u20131234.","DOI":"10.1038\/nm1102-1227"},{"key":"2019111713463060700_B9","doi-asserted-by":"crossref","unstructured":"Nieswandt B, Brakebusch C, Bergmeier W, et al. Glycoprotein VI but not \u03b12\u03b21 integrin is essential for platelet interaction with collagen. EMBO J2001; 20:2120\u20132130.","DOI":"10.1093\/emboj\/20.9.2120"},{"key":"2019111713463060700_B10","doi-asserted-by":"crossref","unstructured":"Williams MS and Bray PF. Genetics of arterial prothrombotic risk states. Exp Biol Med (Maywood)2001; 226:409\u2013419.","DOI":"10.1177\/153537020122600504"},{"key":"2019111713463060700_B11","doi-asserted-by":"crossref","unstructured":"Afshar-Kharghan V, Li CQ, Khoshnevis-Asl M, Lo\u0301pez JA. Kozak sequence polymorphism of the glycoprotein (GP) Ib\u03b1 gene is a major determinant of the plasma membrane levels of the platelet GP Ib- IX-V complex. Blood1999; 94:186\u2013191.","DOI":"10.1182\/blood.V94.1.186.413k19_186_191"},{"key":"2019111713463060700_B12","doi-asserted-by":"crossref","unstructured":"Meisel C, Afshar-Kharghan V, Cascorbi I, et al. Role of Kozak sequence polymorphism of platelet glycoprotein Ibalpha as a risk factor for coronary artery disease and catheter interventions. J Am Coll Cardiol2001; 38:1023\u20131027.","DOI":"10.1016\/S0735-1097(01)01475-9"},{"key":"2019111713463060700_B13","doi-asserted-by":"crossref","unstructured":"Kenny D, Muckian C, Fitzgerald DJ, Cannon CP, Shields DC. Platelet glycoprotein Ib alpha receptor polymorphisms and recurrent ischaemic events in acute coronary syndrome patients. J Thromb Thrombolysis2002; 13:13\u201319.","DOI":"10.1023\/A:1015307823578"},{"key":"2019111713463060700_B14","doi-asserted-by":"crossref","unstructured":"Corral J, Lozano ML, Gonzalez-Conejero R, et al. A common polymorphism flanking the ATG initiator codon of GPIb\u03b1 does not affect expression and is not a major risk factor for arterial thrombosis. Thromb Haemost2000; 83:23\u201328.","DOI":"10.1055\/s-0037-1613751"},{"key":"2019111713463060700_B15","doi-asserted-by":"crossref","unstructured":"Frank MB, Reiner AP, Schwartz SM, et al. The Kozak sequence polymorphism of platelet glycoprotein Ib\u03b1 and risk of nonfatal myocardial infarction and nonfatal stroke in young women. Blood2001; 97:875\u2013879.","DOI":"10.1182\/blood.V97.4.875"},{"key":"2019111713463060700_B16","doi-asserted-by":"crossref","unstructured":"Douglas H, Michaelides K, Gorog DA, et al. Platelet membrane glycoprotein Ibalpha gene -5T\/C Kozak sequence polymorphism as an independent risk factor for the occurrence of coronary thrombosis. Heart2002; 87:70\u201374.","DOI":"10.1136\/heart.87.1.70"},{"key":"2019111713463060700_B17","doi-asserted-by":"crossref","unstructured":"Croft SA, Samani NJ, Teare MD, et al. Novel platelet membrane glycoprotein VI dimorphism is a risk factor for myocardial infarction. Circulation2001; 104:1459\u20131463.","DOI":"10.1161\/hc3801.096397"},{"key":"2019111713463060700_B18","doi-asserted-by":"crossref","unstructured":"Ollikainen E, Mikkelsson J, Perola M, Penttila A, Karhunen PJ. Platelet membrane collagen receptor glycoprotein VI polymorphism is associated with coronary thrombosis and fatal myocardial infarction in middle-aged men. Atherosclerosis2004; 176:95\u201399.","DOI":"10.1016\/j.atherosclerosis.2004.03.021"},{"key":"2019111713463060700_B19","doi-asserted-by":"crossref","unstructured":"Joutsi-Korhonen L, Smethurst PA, Rankin A, et al. The low-frequency allele of the platelet collagen signaling receptor glycoprotein VI is associated with reduced functional responses and expression. Blood2003; 101:4372\u20134379.","DOI":"10.1182\/blood-2002-08-2591"},{"key":"2019111713463060700_B20","doi-asserted-by":"crossref","unstructured":"Marenberg ME, Risch N, Berkman LF, Floderus B, de Faire U. Genetic susceptibility to death from coronary heart disease in a study of twins. N Engl J Med1994; 330:1041\u20131046.","DOI":"10.1056\/NEJM199404143301503"},{"key":"2019111713463060700_B21","doi-asserted-by":"crossref","unstructured":"Harvald B and Hauge M. Coronary occlusion in twins. Acta Genet Med Gemellol (Roma)1970; 19:248\u2013250.","DOI":"10.1017\/S1120962300025609"},{"key":"2019111713463060700_B22","doi-asserted-by":"crossref","unstructured":"Pastinen T, Perola M, Niini P, et al. Array-based multiplex analysis of candidate genes reveals two independent and additive genetic risk factors for myocardial infarction in the Finnish population. Hum Mol Genet1998; 7:1453\u20131462.","DOI":"10.1093\/hmg\/7.9.1453"},{"key":"2019111713463060700_B23","doi-asserted-by":"crossref","unstructured":"Miller ME, Dores GM, Thorpe SL, Akerley WL. Paradoxical influence of estrogenic hormones on platelet-endothelial cell interactions. Thromb Res1994; 74:577\u2013594.","DOI":"10.1016\/0049-3848(94)90215-1"},{"key":"2019111713463060700_B24","doi-asserted-by":"crossref","unstructured":"Thijs A, van Baal WM, van der Mooren MJ, et al. Effects of hormone replacement therapy on blood platelets. Eur J Clin Invest2002; 32:613\u2013618.","DOI":"10.1046\/j.1365-2362.2002.01039.x"},{"key":"2019111713463060700_B25","doi-asserted-by":"crossref","unstructured":"Richard-Davis G, Montgomery-Rice V, Mammen EF, et al. In vitro platelet function in controlled ovarian hyperstimulation cycles. Fertil Steril1997; 67:923\u2013927.","DOI":"10.1016\/S0015-0282(97)81408-2"},{"key":"2019111713463060700_B26","doi-asserted-by":"crossref","unstructured":"Feng D, Lindpaintner K, Larson MG, et al. Increased platelet aggregability associated with platelet GPIIIa PlA2 polymorphism: the Framingham Offspring Study. Arterioscler Thromb Vasc Biol1999; 19:1142\u20131147.","DOI":"10.1161\/01.ATV.19.4.1142"},{"key":"2019111713463060700_B27","doi-asserted-by":"crossref","unstructured":"Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen\/progestin Replacement Study follow-up (HERS II). JAMA2002; 288:49\u201357.","DOI":"10.1001\/jama.288.1.49"},{"key":"2019111713463060700_B28","doi-asserted-by":"crossref","unstructured":"Grady D, Applegate W, Bush T, et al. Heart and Estrogen\/progestin Replacement Study (HERS): design, methods, and baseline characteristics. Control Clin Trials1998; 19:314\u2013335.","DOI":"10.1016\/S0197-2456(98)00010-5"},{"key":"2019111713463060700_B29","doi-asserted-by":"crossref","unstructured":"Wacholder S, Chanock S, Garcia-Closas M, El GL, Rothman N. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst2004; 96:434\u2013442.","DOI":"10.1093\/jnci\/djh075"},{"key":"2019111713463060700_B30","doi-asserted-by":"crossref","unstructured":"Yee DL and Bray PF. Clinical and functional consequences of platelet membrane glycoprotein polymorphisms. Semin Thromb Hemost2004; 30:591\u2013600.","DOI":"10.1055\/s-2004-835679"},{"key":"2019111713463060700_B31","doi-asserted-by":"crossref","unstructured":"Takagi S, Iwai N, Baba S, et al. A GPVI polymorphism is a risk factor for myocardial infarction in Japanese. Atherosclerosis2002; 165:397\u2013398.","DOI":"10.1016\/S0021-9150(02)00241-1"},{"key":"2019111713463060700_B32","doi-asserted-by":"crossref","unstructured":"Best D, Senis YA, Jarvis GE, et al. GPVI levels in platelets: relationship to platelet function at high shear. Blood2003; 102:2811\u20132818.","DOI":"10.1182\/blood-2003-01-0231"},{"key":"2019111713463060700_B33","doi-asserted-by":"crossref","unstructured":"Glueck CJ, Wang P, Fontaine RN, et al. Effect of exogenous estrogen on atherothrombotic vascular disease risk related to the presence or absence of the factor V Leiden mutation (resistance to activated protein C). Am J Cardiol1999; 84:549\u2013554.","DOI":"10.1016\/S0002-9149(99)00375-6"},{"key":"2019111713463060700_B34","doi-asserted-by":"crossref","unstructured":"Psaty BM, Smith NL, Lemaitre RN, et al. Hormone replacement therapy, prothrombotic mutations, and the risk of incident nonfatal myocardial infarction in postmenopausal women. JAMA2001; 285:906\u2013913.","DOI":"10.1001\/jama.285.7.906"},{"key":"2019111713463060700_B35","doi-asserted-by":"crossref","unstructured":"Herrington DM, Howard TD, Hawkins GA, et al. Estrogen-receptor polymorphisms and effects of estrogen replacement on high-density lipoprotein cholesterol in women with coronary disease. N Engl J Med2002; 346:967\u2013974.","DOI":"10.1056\/NEJMoa012952"},{"key":"2019111713463060700_B36","doi-asserted-by":"crossref","unstructured":"Salmen T, Heikkinen AM, Mahonen A, et al. Early postmenopausal bone loss is associated with PvuII estrogen receptor gene polymorphism in Finnish women: effect of hormone replacement therapy. J Bone Miner Res2000; 15:315\u2013321.","DOI":"10.1359\/jbmr.2000.15.2.315"},{"key":"2019111713463060700_B37","doi-asserted-by":"crossref","unstructured":"Chen FP, Lee N, Wang CH, Cherng WJ, Soong YK. Effects of hormone replacement therapy on cardiovascular risk factors in postmenopausal women. Fertil Steril1998; 69:267\u2013273.","DOI":"10.1016\/S0015-0282(97)00487-1"},{"key":"2019111713463060700_B38","doi-asserted-by":"crossref","unstructured":"Cadroy Y, Sakariassen KS, Charlet JP, et al. Role of 4 platelet membrane glycoprotein polymorphisms on experimental arterial thrombus formation in men. Blood2001; 98:3159\u20133161.","DOI":"10.1182\/blood.V98.10.3159"},{"key":"2019111713463060700_B39","doi-asserted-by":"crossref","unstructured":"Leng X-H and Bray PF. Hormone therapy and platelet function. Drug Discov Today2005; 2:85\u201391.","DOI":"10.1016\/j.ddmec.2005.05.028"},{"key":"2019111713463060700_B40","doi-asserted-by":"crossref","unstructured":"Khetawat G, Faraday N, Nealen ML, et al. Human megakaryocytes and platelets contain the estrogen receptor \u03b2 and androgen receptor (AR): testosterone regulates AR expression. Blood2000; 95:2289\u20132296.","DOI":"10.1182\/blood.V95.7.2289.007k03_2289_2296"},{"key":"2019111713463060700_B41","doi-asserted-by":"crossref","unstructured":"Leng XH, Zhang W, Nieswandt B, Bray PF. Effects of estrogen replacement therapies on mouse platelet function and glycoprotein VI levels. Circ Res2005; 97:415\u2013417.","DOI":"10.1161\/01.RES.0000181025.43762.cf"},{"key":"2019111713463060700_B42","doi-asserted-by":"crossref","unstructured":"Arthur JF, Gardiner EE, Matzaris M, et al. Glyco-protein VI is associated with GPIb-IX-V on the membrane of resting and activated platelets. Thromb Haemost2005; 93:716\u2013723.","DOI":"10.1160\/TH04-09-0584"},{"key":"2019111713463060700_B43","doi-asserted-by":"crossref","unstructured":"Herrington D. Eliminating the improbable: Sherlock Holmes and standards of evidence in the genomic age. Circulation2005; 112:2081\u20132084.","DOI":"10.1161\/CIRCULATIONAHA.105.570069"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/109\/5\/1862\/1478818\/zh800507001862.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/109\/5\/1862\/1478818\/zh800507001862.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T13:46:53Z","timestamp":1573998413000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/109\/5\/1862\/23221\/Effect-of-genetic-variations-in-platelet"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,11,14]]},"references-count":43,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2006,11,14]]},"published-print":{"date-parts":[[2007,3,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2006-03-013151","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1086776.539693","asserted-by":"object"}]},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,11,14]]}}}